R. S. Melo and F. R. Marques, “Exclusion payment agreements between reference and generic drug companies: restrictive practices of competition?”, PIDCC, vol. 4, no. 1, pp. 392–420, Feb. 2015, doi: 10.16928/2316-8080.v8n1p.392-420.